Prostate stem cell antigen: A Jekyll and Hyde molecule?

Clinical Cancer Research

Volumn 16, Issue 14, 2010, Pages 3533-3538

  Saeki, Norihisa ^a   Gu, Jian ^b   Yoshida, Teruhiko ^a   Wu, Xifeng ^b  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE PROTEIN; DENDRITIC CELL VACCINE; GLYCOSYLPHOSPHATIDYLINOSITOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1G8; PROSTATE SPECIFIC ANTIGEN; PROSTATE STEM CELL ANTIGEN; PROVENGE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; BLADDER CANCER; CANCER CELL; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CYTODIAGNOSIS; CYTOTOXICITY; DENDRITIC CELL; DOWN REGULATION; ESOPHAGUS CANCER; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HORMONAL THERAPY; HUMAN; IMMUNOCYTOCHEMISTRY; METASTASIS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMACH EPITHELIUM; TRANSITIONAL CELL CARCINOMA; TUMOR IMMUNITY; UPREGULATION;

ANTIGENS, NEOPLASM; FEMALE; GPI-LINKED PROTEINS; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 77954748206     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3169     Document Type: Review

References (63)

1. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 1998;95:1735-40.
2. Bahrenberg G, Brauers A, Joost HG, et al. Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors. Biochem Biophys Res Commun 2000;275:783-8.
3. Gu Z, Thomas G, Yamashiro J, et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000;19:1288-96.
4. de Nooij-van Dalen AG, van Dongen GA, Smeets SJ, et al. Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcinoma. Int J Cancer 2003;103:768-74.
5. Tran CP, Lin C, Yamashiro J, et al. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res 2002;1:113-21.
6. Sakamoto H, Yoshimura K, Saeki N, et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet 2008;40:730-40.
7. Moore ML, Teitell MA, Kim Y, et al. Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation. Prostate 2008;68:139-51. (Pubitemid 351186226)
8. Bamezai A. Mouse Ly-6 proteins and their extended family: markers of cell differentiation and regulators of cell signaling. Arch Immunol Ther Exp (Warsz) 2004;52:255-66. (Pubitemid 39331159)
9. Hruska M, Keefe J, Wert D, et al. Prostate stem cell antigen is an endogenous lynx1-like prototoxin that antagonizes α7-containing nicotinic receptors and prevents programmed cell death of parasympathetic neurons. J Neurosci 2009;29:14847-54.
10. Amara N, Palapattu GS, Schrage M, et al. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res 2001;61:4660-5. (Pubitemid 32691871)
11. Elsamman EM, Fukumori T, Tanimoto S, et al. The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantitative reverse transcriptase-polymerase chain reaction analysis. BJU Int 2006;98:668-73. (Pubitemid 44185896)
12. Argani P, Rosty C, Reiter RE, et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 2001;61:4320-4.
13. Feng HC, Tsao SW, Ngan HY, et al. Overexpression of prostate stem cell antigen is associated with gestational trophoblastic neoplasia. Histopathology 2008;52:167-74.
14. Cao D, Ji H, Ronnett BM. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int J Gynecol Pathol 2005;24:67-72.
15. Jain A, Lam A, Vivanco I, et al. Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. Mol Endocrinol 2002;16:2323-37.
16. Watabe T, Lin M, Ide H, et al. Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter. Proc Natl Acad Sci U S A 2002;99:401-6. (Pubitemid 34060373)
17. Zhigang Z, Wenlu S. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma. Prostate 2005;65:299-305. (Pubitemid 41759961)
18. Bahrenberg G, Brauers A, Joost HG, et al. PSCA expression is regulated by phorbol ester and cell adhesion in the bladder carcinoma cell line RT112. Cancer Lett 2001;168:37-43. (Pubitemid 32463910)
19. Chapman EJ, Kelly G, Knowles MA. Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells. Mol Cancer Res 2008;6:1154-68.
20. Chatterjee S, Mayor S. The GPI-anchor and protein sorting. Cell Mol Life Sci 2001;58:1969-87.
21. Tsuchida K, Nakatani M, Hitachi K, et al. Activin signaling as an emerging target for therapeutic interventions. Cell Commun Signal 2009;7:15.
22. Gupta A, Van Vlijmen HW, Singh J. A classification of disulfide patterns and its relationship to protein structure and function. Protein Sci 2004;13:2045-58. (Pubitemid 38989611)
23. Saffran DC, Raitano AB, Hubert RS, et al. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A 2001;98:2658-63.
24. Gu Z, Yamashiro J, Kono E, et al. Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer Res 2005;65:9495-500. (Pubitemid 41508019)
25. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009;9:874-85.
26. Yang L, Han Y, Suarez Saiz F, et al. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007;21:868-76. (Pubitemid 46672061)
27. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 2003;3:756-67.
28. Han KR, Seligson DB, Liu X, et al. Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol 2004;171:1117-21. (Pubitemid 38327539)
29. Zhigang Z, Wenlv S. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World J Surg Oncol 2004;2:13.
30. Lam JS, Yamashiro J, Shintaku IP, et al. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res 2005;11:2591-6.
31. Reiter RE, Sato I, Thomas G, et al. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer 2000;27:95-103.
32. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008;8:976-90.
33. Zhigang Z, Wenlu S. Prostate stem cell antigen (PSCA) mRNA expression in prostatic intraepithelial neoplasia: implications for the development of prostate cancer. Prostate 2007;67:1143-51.
34. Zhigang Z, Wenlu S. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate. Prostate 2008;68:190-9. (Pubitemid 351186231)
35. Zhao Z, Liu J, Li S, et al. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia. Prostate 2009;69:1292-302.
36. Ananias HJ, van den Heuvel MC, Helfrich W, et al. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 2009;69:1101-8.
37. Hara N, Kasahara T, Kawasaki T, et al. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. Clin Cancer Res 2002;8:1794-9.
38. Helo P, Cronin AM, Danila DC, et al. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. Clin Chem 2009;55:765-73.
39. Joung JY, Cho KS, Kim JE, et al. Prostate stem cell antigen mRNA in peripheral blood as a potential predictor of biochemical recurrence in high-risk prostate cancer. J Surg Oncol 2010;101:145-8.
40. Zhigang Z, Wenlu S. Flutamide reduced prostate cancer development and prostate stem cell antigen mRNA expression in high grade prostatic intraepithelial neoplasia. Int J Cancer 2008;122:864-70.
41. Zhigang Z, Wenlu S. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer. Prostate 2007;67:653-60. (Pubitemid 46685286)
42. Damber JE, Aus G. Prostate cancer. Lancet 2008;371:1710-21.
43. Matera L. The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer. Cancer Treat Rev 2009;36:131-41.
44. Thomas-Kaskel AK, Zeiser R, Jochim R, et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer 2006;119:2428-34. (Pubitemid 44546968)
45. Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, et al. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 2006;55:1524-33. (Pubitemid 44327840)
46. Zhang X, Yu C, Zhao J, et al. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice. J Gene Med 2007;9:715-26. (Pubitemid 47288829)
47. Garcia-Hernandez Mde L, Gray A, Hubby B, et al. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 2008;68:861-9. (Pubitemid 351206764)
48. Ahmad S, Casey G, Sweeney P, et al. Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther 2009;17:1101-8.
49. Morgenroth A, Cartellieri M, Schmitz M, et al. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 2007;67:1121-31. (Pubitemid 46983341)
50. Olafsen T, Gu Z, Sherman MA, et al. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother 2007;30:396-405.
51. Leyton JV, Olafsen T, Lepin EJ, et al. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin Cancer Res 2008;14:7488-96.
52. Leyton JV, Olafsen T, Sherman MA, et al. Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. Protein Eng Des Sel 2009;22:209-16.
53. Cheng L, Reiter RE, Jin Y, et al. Immunocytochemical analysis of prostate stem cell antigen as adjunct marker for detection of urothelial transitional cell carcinoma in voided urine specimens. J Urol 2003;169:2094-100. (Pubitemid 36576725)
54. Elsamman E, Fukumori T, Kasai T, et al. Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder. BJU Int 2006;97:1202-7. (Pubitemid 43907322)
55. McCarthy DM, Maitra A, Argani P, et al. Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases. Appl Immunohistochem Mol Morphol 2003;11:238-43. (Pubitemid 37082060)
56. Lukyanchuk VV, Friess H, Kleeff J, et al. Detection of circulating tumor cells by cytokeratin 20 and prostate stem cell antigen RT-PCR in blood of patients with gastrointestinal cancers. Anticancer Res 2003;23:2711-6.
57. Tanaka M, Komatsu N, Terakawa N, et al. Increased levels of IgG antibodies against peptides of the prostate stem cell antigen in the plasma of pancreatic cancer patients. Oncol Rep 2007;18:161-6.
58. Foss CA, Fox JJ, Feldmann G, et al. Radiolabeled anti-claudin 4 and anti-prostate stem cell antigen: initial imaging in experimental models of pancreatic cancer. Mol Imaging 2007;6:131-9.
59. Yong KT, Ding H, Roy I, et al. Imaging pancreatic cancer using bioconjugated InP quantum dots. ACS Nano 2009;3:502-10.
60. Wente MN, Jain A, Kono E, et al. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas 2005;31:119-25.
61. Wu X, Ye Y, Kiemeney LA, et al. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 2009;41:991-5.
62. Lu Y, Chen J, Ding Y, et al. Genetic variation of PSCA gene is associated with the risk of both diffuse- and intestinal-gastric cancer in a Chinese population. Int J Cancer 2010, Epub 2010 Feb 3.
63. Wang S, Tang J, Wang M, Yuan L, Zhang Z. Genetic variation in PSCA and bladder cancer susceptibility in a Chinese population. Carcinogenesis 2010;31:621-4.